Gustave Roussy Selects TrialMaster EDC to Support Cancer Research
FORT LAUDERDALE, FL., July 05, 2017 (GLOBE NEWSWIRE)-Gustave Roussy, the cancer research institute in Europe, has selected TrialMaster electronic data capture (EDC) technology from OmniComm Systems, Inc., a global provider of clinical data management technology. OmniComm’s TrialMaster will support Gustave Roussy-sponsored clinical trials in oncology that are handled and analyzed by Gustave Roussy’s biostatistics and epidemiology unit. Gustave Roussy focuses on patient care, research, and teaching for all types of cancer.
TrialMaster was chosen because of certain features, including the ability to build studies, adeptness in query management workflow, intuitive interface, monitoring and centralized source review, eLearning modules, exporting abilities, and the range of report types.
“To have an institution as prestigious as Gustave Roussy select TrialMaster is a real testament to the quality, flexibility and scalability of both our EDC technology and our business operations. Moreover, we are incredibly proud to have been selected as their EDC partner,” said Kuno van der Post, OmniComm’s chief commercial officer. “TrialMaster has seen a great deal of well-publicized success over the last 18 months within the academic sector. Coupled with our deployments over that same time period in both pharmacompanies and CROs, it adds up to an achievement that cannot be emulated by many of the EDC systems available today.”
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KVanderPost@omnicomm.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
